CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 112 enrolled
Drug / intervention
Reveal LINQ™ Insertable Cardiac Monitor (ICM)device
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02758301
NCT02758301N/ACompleted
CompareCT.gov

Reveal LINQ™ Heart Failure

Medtronic Cardiac Rhythm and Heart Failure·observational·Posted May 2, 2016·Updated Nov 12, 2019

In Brief

An observational study evaluating Reveal LINQ™ Insertable Cardiac Monitor (ICM) for Heart Failure. Completed, enrolled 112 participants across 19 sites.

Detailed Summary

The purpose of the LINQ™ HF study is to characterize Reveal LINQ™ derived data from patients with heart failure by assessing the relationship between changes in LINQ™ derived data and other physiologic parameters with subsequent acute decompensated heart failure (ADHF) events.

Study Details

Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsHeart Failure
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedMay 2, 2016
Enrollment StartJun 8, 2016
Primary CompletionDec 4, 2018
TodayJul 2, 2026
Enrollment to primary: 2.5 yearsPosted 10.2 years ago

Interventions

Reveal LINQ™ Insertable Cardiac Monitor (ICM)device

Insertable Cardiac Monitor with LINQ™ HF Investigational RAMware download